Open access
Jul 2026
Targeted α-synuclein mRNA degradation by PMO-based RNA-degrading chimeras.
Findings indicate that PMO-based RNA-degrading chimeras (RDCs) that selectively bind the 5' untranslated region of SNCA messenger RNA (mRNA) and recruit RNase L for targeted RNA degradation may represent a promising therapeutic modality for α-synucleinopathies.
Ning Wang, Shalakha Hegde, Zhichao Tang et al.
· Proceedings of the National... · 0 citations